{
  "clinical_summary": {
    "etiology": "HCV-related cirrhosis",
    "symptoms": [
      "Decompensated cirrhosis (no ascites)",
      "No abdominal pain",
      "No weight loss",
      "No palpable abdominal mass"
    ],
    "comorbidities": ["Type 2 Diabetes Mellitus", "Hypertension"],
    "ascites": "none",
    "encephalopathy": "none",
    "ECOG": 0,
    "labs_baseline": {
      "hemoglobin_g_dl": 11.4,
      "WBC_k": 6.25,
      "platelets_k": 88.0,
      "total_bilirubin_mg_dl": 1.2,
      "direct_bilirubin_mg_dl": 0.38,
      "AST_U_L": 55.0,
      "ALT_U_L": 29.0,
      "ALP_U_L": 170.4,
      "albumin_g_dl": 2.87,
      "INR": 1.2,
      "PT_sec": 13.9,
      "Na_mmol_L": 136.0,
      "creatinine_mg_dl": 0.78,
      "AFP_ng_ml": 33.78,
      "CRP_mg_L": null
    },
    "labs_time_series": [],
    "derived_scores": {
      "Child_Pugh": {
        "score": 6,
        "class": "A",
        "components": {
          "bilirubin": 1,
          "albumin": 2,
          "INR": 1,
          "ascites": 1,
          "encephalopathy": 1
        }
      },
      "MELD": 9,
      "MELD_Na": 7,
      "ALBI": {
        "score": -1.573,
        "grade": 2
      }
    },
    "lab_flags": {
      "hemoglobin_g_dl": "low",
      "WBC_k": "normal",
      "platelets_k": "low",
      "total_bilirubin_mg_dl": "normal",
      "direct_bilirubin_mg_dl": "high",
      "AST_U_L": "high",
      "ALT_U_L": "normal",
      "ALP_U_L": "high",
      "albumin_g_dl": "low",
      "INR": "normal",
      "PT_sec": "normal",
      "Na_mmol_L": "normal",
      "creatinine_mg_dl": "normal",
      "AFP_ng_ml": "high",
      "CRP_mg_L": null
    },
    "clinical_interpretation": "The patient has HCV-related cirrhosis with a Child-Pugh score of 6, indicating compensated liver function, and a MELD-Na score of 7, suggesting relatively preserved hepatic function. The absence of ascites and encephalopathy, along with no reported symptoms of abdominal pain or weight loss, supports a stable clinical status. The elevated AFP level of 33.78 ng/ml is notable and may warrant further evaluation for hepatocellular carcinoma. Baseline lab abnormalities include low hemoglobin and platelets, high direct bilirubin, AST, and ALP, and low albumin.\n\nNo follow-up lab data available."
  },
  "agent_metadata": {
    "clinical_agent_confidence": 0.94
  },
  "ground_truth": {
    "clinical_scores": {
      "Child_Pugh": {
        "score": 6,
        "class": "A"
      },
      "MELD": null,
      "MELD_Na": null,
      "ALBI": {
        "score": null,
        "grade": null
      }
    }
  },
  "radiology_summary": {
    "studies": [
      {
        "date": null,
        "modality": "CT / MRI Multiphasic (LI-RADS Assessment)",
        "lesions": [
          {
            "lesion_id": "L1",
            "segment": null,
            "size_cm": {
              "longest_diameter_cm": 4.5,
              "transverse_cm": null
            },
            "enhancement_features": {
              "arterial_phase_hyperenhancement": true,
              "washout": true,
              "enhancing_capsule": null,
              "threshold_growth": null
            },
            "ground_truth_li_rads": "LR-5",
            "derived_li_rads": "LR-5",
            "pvtt": false,
            "extrahepatic_metastasis": false,
            "treated": false
          }
        ],
        "radiology_report_text": "Single hepatic lesion measuring 4.5 cm demonstrating arterial phase hyperenhancement with washout. Classified as LI-RADS LR-5. No portal vein tumor thrombus noted.",
        "overall_derived_li_rads": "LR-5"
      },
      {
        "date": null,
        "modality": "Post-TACE follow-up imaging",
        "lesions": [
          {
            "lesion_id": "L1",
            "segment": null,
            "size_cm": {
              "longest_diameter_cm": null,
              "transverse_cm": null
            },
            "enhancement_features": {
              "arterial_phase_hyperenhancement": true,
              "washout": null,
              "enhancing_capsule": null,
              "threshold_growth": null
            },
            "ground_truth_li_rads": "LR-TR-Viable",
            "derived_li_rads": "LR-TR-Viable",
            "pvtt": false,
            "extrahepatic_metastasis": false,
            "treated": true
          }
        ],
        "radiology_report_text": "Post-treatment imaging demonstrates partial response with residual viable enhancing tumor consistent with LR-TR Viable.",
        "overall_derived_li_rads": "LR-TR-Viable"
      }
    ],
    "temporal_response": {
      "mRECIST": {
        "category": "INSUFFICIENT_DATA: current_study_size_missing",
        "baseline_viable_diameter_cm": 4.5,
        "current_viable_diameter_cm": null,
        "percent_change": null
      },
      "LI_RADS_TR": "LR-TR-Viable"
    },
    "tumor_burden": {
      "metric": "TBS",
      "value": 4.61
    },
    "radiology_interpretation": "Baseline LR-5 lesion measuring 4.5 cm. Treatment response assessment limited by incomplete follow-up imaging data.",
    "agent_metadata": {
      "radiology_agent_confidence": 0.9
    }
  },
  "pathology_summary": {
    "biopsy_performed": false,
    "histology": {
      "diagnosis": null,
      "differentiation": null,
      "fibrosis_stage": null,
      "steatosis_percent": null,
      "steatosis_grade": null,
      "lobular_inflammation": null,
      "ballooning": null,
      "vascular_invasion": null,
      "comments": "No biopsy performed."
    },
    "molecular_profile": {
      "TERT_promoter_mutation": "not_reported",
      "TP53_mutation": "not_reported",
      "CTNNB1_mutation": "not_reported",
      "MSI_status": "not_reported",
      "PDL1_IHC": "not_reported",
      "TMB": "not_reported"
    },
    "source_text": {
      "pathology_report_text": "",
      "molecular_profile_text": ""
    },
    "pathology_interpretation": "No biopsy performed; pathology data unavailable.",
    "agent_metadata": {
      "pathology_agent_confidence": 1.0
    }
  },

  "notes_summary": {
    "tumor_board_text": "The tumor board, comprising hepatologists, hepatobiliary surgeons, interventional radiologists, medical oncologists, radiation oncologists, pathologists, and radiologists, discussed a case of HCV-related cirrhosis with a 4.5 cm LI-RADS LR-5 HCC, classified as Child-Pugh class A and BCLC stage A. Initial treatment with TACE resulted in a partial response, but imaging revealed a viable residual tumor. The board recommended repeating locoregional therapy if feasible, with systemic immunotherapy as a contingency for disease progression. Regular monitoring with AFP, PIVKA-II, and contrast-enhanced CT/MRI every 2-3 months was advised.",
    "treatment_history": {
      "previous": ["TACE"],
      "current": "",
      "response": "Partial response with viable residual tumor."
    },
    "board_members": [
      "Hepatologist",
      "Hepatobiliary Surgeon",
      "Interventional Radiologist",
      "Medical Oncologist",
      "Radiation Oncologist",
      "Pathologist",
      "Radiologist"
    ]
  }
}
